After seeing its GSK-backed trial ditched, LAG-3-focused Immutep secures cash, plots new trial push

Australian biotech Immutep has secured $60 million Australian dollars through a “two-tranche institutional placement” as it eyes a deeper push into the clinic and looks to raise a further AU$5 million via a share purchase plan.